ArticleACS biomaterials science & engineering2025
BSA-LDHs-cGAMP In Situ Sensitization of Osteosarcoma: Enhancing Antitumor Efficacy with CD40 Agonist Antibodies.
Article in ACS biomaterials science & engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dynamic immune state transitions and metastatic niche remodelling drive osteosarcoma evolution as a barrier-restricted immune-cold ecosystem.Frontiers in immunology · 2026Review
- Stimuli-responsive nanoplatforms for precision activation of the STING pathway in cancer immunotherapy.Frontiers in immunology · 2026Review
- In Situ Development of Quercetin-Enhanced Layered Double Hydroxides for Targeted Osteosarcoma Therapy.ACS biomaterials science & engineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteosarcoma is a malignant bone tumor that is extremely aggressive and presents several therapeutic problems. Although CD40 agonist antibodies (αCD40) have demonstrated potential in improving T cell priming and reprogramming tumor-associated macrophages, osteosarcoma's poor immunogenicity leads to "cold" tumors that are challenging to cure. When it comes to triggering immunological responses, the STING pathway is essential. To further improve this impact, cGAMP was stabilized and delivered using layered double hydroxide (LDH) nanoparticles cross-linked with bovine serum albumin (BSA). BSA-LDHs-cGAMP improved the infiltration of CD40+ macrophages and DC cells, which, in turn, improved the therapeutic impact of αCD40 immunotherapy. These results offer a promising in situ cancer treatment and show the possibility of αCD40 boosters in bone tumor therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.